Another cancer drug breakthrough for Redx

MERSEYSIDE drug development company Redx Pharma has identified a potential new treatment for blood cancers and autoimmune diseases.

The new drug inhibits Bruton's Tyrosine Kinase (BKT), the enzyme which plays a key role in the development of the illnesses.

Blood cancers include leukaemia such as chronic lymphocytic leukaemia and autoimmune diseases include rheumatoid arthritis, lupus and Sjögren's syndrome.

The "candidate" drug is the company's second to be advanced from its innovative development... You can carry on reading for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...